Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANDRA ECHEGOYEN DAVIS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1215016951
CMS profile
1052491
Location
FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$59.07

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $59.07 4

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan Inc. $32.28 2
Sun Pharmaceutical Industries Inc. $15.67 1
Janssen Pharmaceuticals, Inc $11.12 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANDRA ECHEGOYEN DAVIS

NPI 1215016951 · CMS profile ID 1052491

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215016951?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANDRA ECHEGOYEN DAVIS, NPI 1215016951, CMS profile ID 1052491. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215016951?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SANDRA ECHEGOYEN DAVIS, NPI 1215016951, CMS profile ID 1052491. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215016951?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SANDRA ECHEGOYEN DAVIS, NPI 1215016951, CMS profile ID 1052491, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215016951?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $59.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sun Pharmaceutical Industries Inc. $15.6708/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704598281 CMS
Janssen Pharmaceuticals, Inc $11.1204/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658489087 CMS
Allergan Inc. $14.7902/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670233915 CMS
Allergan Inc. $17.4901/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670233913 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59.07 4
PY2020 $170.43 6
PY2021 $350.38 38
PY2022 $76.87 4
PY2023 $192.51 10
PY2024 $214.67 11
PY2025 $31.77 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $14,677.74 138
PY2019 Principal investigator $96,697.95 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

138 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $80.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109023
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $80.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109025
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $80.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109027
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $158.10 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109029
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $158.10 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109031
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $158.10 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109033
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9.40 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109035
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9.40 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109037
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9.40 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109039
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109041
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109043
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109045
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $140.60 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109047
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $140.60 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109049
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $140.60 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109051
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $140.60 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109053
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $116.82 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109055
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $116.82 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109057
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $116.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109059
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $116.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109061
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $116.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109063
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $116.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109065
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $116.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109067
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $116.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109069
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $116.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109071
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16.30 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109073
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109075
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109077
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109079
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109081
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109083
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109085
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109087
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109089
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109091
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $181.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109093
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $181.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109095
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $176.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109097
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $176.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109099
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $176.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109101
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $176.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109103
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $97.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109105
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109107
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $97.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109109
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109111
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109113
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109115
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109117
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109119
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109121
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109123
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109125
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109127
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $176.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109129
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $106.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109131
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $106.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109133
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $106.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109135
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $106.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109137
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $106.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109139
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $106.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109141
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $106.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109143
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $106.87 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109145
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $106.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109147
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $155.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109149
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $155.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109151
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $155.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109153
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $155.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109155
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $155.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109157
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $155.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109159
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $155.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109161
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $155.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109163
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109165
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109167
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109169
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109171
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109173
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109175
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109177
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109179
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109181
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $119.38 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109183
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $119.38 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109185
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109187
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109189
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109191
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109193
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109195
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109197
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $125.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109199
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109201
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109203
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109205
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109207
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109209
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109211
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109213
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109215
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109217
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109219
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109221
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109223
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109225
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109227
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109229
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20.62 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109231
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $174.38 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109233
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $174.38 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109235
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $174.38 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109237
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $174.38 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109239
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $181.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109241
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $181.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109243
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $181.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109245
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $176.88 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109247
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $80.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109249
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9.38 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109251
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $147.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109253
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $147.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109255
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $147.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109257
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $147.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109259
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $147.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109261
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $147.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109263
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $147.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109265
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $147.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109267
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $147.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109269
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109271
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109273
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109275
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109277
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109279
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109281
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109283
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109285
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109287
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109289
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109291
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109293
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $110.00 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109295
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $122.50 05/29/2020 Non-covered Recipient Entity
North Texas Clinical Trials
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia No dispute reported 06/30/2026 740109297